Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $11.2 million.

  • Nurix Therapeutics' Accounts Payables fell 232.54% to $11.2 million in Q4 2025 from the same period last year, while for Nov 2025 it was $11.2 million, marking a year-over-year decrease of 232.54%. This contributed to the annual value of $11.2 million for FY2025, which is 232.54% down from last year.
  • Nurix Therapeutics' Accounts Payables amounted to $11.2 million in Q4 2025, which was down 232.54% from $8.6 million recorded in Q3 2025.
  • Nurix Therapeutics' 5-year Accounts Payables high stood at $11.5 million for Q4 2024, and its period low was $2.2 million during Q3 2023.
  • Over the past 5 years, Nurix Therapeutics' median Accounts Payables value was $5.9 million (recorded in 2024), while the average stood at $6.0 million.
  • In the last 5 years, Nurix Therapeutics' Accounts Payables tumbled by 6386.92% in 2023 and then soared by 11972.95% in 2025.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Accounts Payables stood at $6.6 million in 2021, then decreased by 23.85% to $5.1 million in 2022, then grew by 26.4% to $6.4 million in 2023, then surged by 79.38% to $11.5 million in 2024, then fell by 2.33% to $11.2 million in 2025.
  • Its last three reported values are $11.2 million in Q4 2025, $8.6 million for Q3 2025, and $6.0 million during Q2 2025.